Abbreviation: PTLD, post-transplant lymphoproliferative disorder; TCR,
T-cell gene rearrangement; EBV, Epstein Barr virus; CHOP,
cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and the
steroid hormone prednisone. EPOCH, etoposide phosphate, prednisone,
vincristine sulfate (Oncovin), cyclophosphamide, and doxorubicin
hydrochloride (hydroxydaunorubicin). ASCT, autologous stem cell
transplant. N/A, not available.
Figure 1: Pathology features of plasmablastic lymphoma post
solid organ transplant. A-B, the H&E section of intestinal mass (H&E,
A, 20X; B, 400x) and the touch imprint (C, Diff-Quick stain,1000x) shows
a diffuse infiltrate of plasmablastic tumor cells. By
immunohistochemical stain, the tumor cells are negative for CD20 (not
shown); positive for patchy CD79a (D, 200X), CD30 (E, 200X), cytoplasmic
CD3 (F, 200X), high Ki67 proliferation rate (G, 200X); negative for EBER
in situ hybridization (H, 200X). Most tumor cells are negative for CD138
(I, 200x).